Head-to-head evidence
ACI-35.030 vs Bepranemab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Tau (monoclonal antibody) · full Alzheimer's Disease pipeline
ACI-35.030
Developed by AC Immune and partners
NCT04445831 · Phase 1/2 · completed
This was a randomized, quadruple-blinded, placebo-controlled study, which is a strong design foundation, but the enrollment was very small (57 participants split across seven arms, several with only 4-6 subjects), and the primary endpoints were safety/tolerability counts and antibody-titer levels rather than a hard clinical or cognitive outcome - cognitive and functional scales (CDR-SB, RBANS, NPI) were only exploratory and their results were not even posted. Because the primary comparisons here are immunogenicity/safety readouts rather than a statistically tested clinical efficacy endpoint, this evidence is real but limited.
Bepranemab
Developed by UCB
NCT04867616 · Phase 2 · completed
The study randomized 466 participants to two bepranemab dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary clinical endpoint was change in CDR-SB at Week 80, but whether this endpoint was met cannot be determined because results are not posted.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACI-35.030's landscape · Bepranemab's landscape